<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01432873</url>
  </required_header>
  <id_info>
    <org_study_id>HORCSCT-9001</org_study_id>
    <nct_id>NCT01432873</nct_id>
  </id_info>
  <brief_title>Oral Selenium Therapy for the Prevention of Mucositis</brief_title>
  <official_title>A Randomized Double Blinded Placebo Controlled Oral Selenium Therapy for the Prevention of Mucositis in Patients Undergoing High Dose Chemotherapy With Hematopoietic Stem Cell Transplantation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Tehran University of Medical Sciences</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Tehran University of Medical Sciences</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Selenium as an antioxidant and anti-inflammatory agent could be effective in prevention of
      mucositis induced by chemotherapy and radiotherapy. Other agents such as vitamin E, Zinc
      sulfate, amifostine, beta carotene and benzidamine are indicated for prevention of mucositis
      and positive effects are seen. Our purpose in this double blinded randomized study is to
      evaluate the selenium effect on mucositis prevention in patient with acute myeloid leukemia
      (AML) &amp; acute lymphoblastic leukemia (ALL) whose received Busulfan and/or Cyclophosphamide
      before Hematopoietic stem cell transplantation (HSCT).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients with AML or ALL diagnosis, candidates for high dose chemotherapy with stem cell
      transplantation will be screened for enrollment in the study.

      Patients will be randomized in two groups with balanced block randomization method. One group
      will receive selenium tablet twice per day and another group will receive placebo two times
      per day.Therapy will start on the morning before starting chemotherapy and will continue
      until the first of either discharge day or day +21.

      Response assessment will include:

        1. Mucositis assessment using WHO grading and OMAS scores- to be done from baseline and
           until day +21 or discharge day if before day +21.

        2. Evaluation of selenium and glutathione peroxidase levels in the serum, - to be done at
           baseline, day +7 and day +14.

        3. Collection of clinical outcome data regarding infectious complications including-
           presence and length of febrile neutropenia, use of antibacterial and antifungal
           medications
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>June 2011</start_date>
  <completion_date type="Anticipated">December 2012</completion_date>
  <primary_completion_date type="Anticipated">October 2012</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The grade of oral mucositis after bone marrow transplantation</measure>
    <time_frame>Participants will be followed for the duration of hospital stay, an expected average of 3 weeks</time_frame>
    <description>The effect of oral selenium on prevention of mucositis in patients undergoing bone marrow transplantation</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Evaluation of selenium concentration and glutathione peroxidase level in serum</measure>
    <time_frame>up to 3 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total days of mucositis after BMT</measure>
    <time_frame>Participants will be followed for the duration of hospital stay, an expected average of 3 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">76</enrollment>
  <condition>Mucositis</condition>
  <condition>Hematopoietic Stem Cell Transplantation</condition>
  <arm_group>
    <arm_group_label>Experimental</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Oral selenium therapy arm</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Oral placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oral selenium</intervention_name>
    <description>Drug: selenium tablet Oral selenium 1 Tab bid from day -6/-7 until discharge</description>
    <arm_group_label>Experimental</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oral placebo</intervention_name>
    <description>Drug: Placebo Oral placebo 1 Tab bid from day -6/-7 until discharge</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with AML or ALL undergoing high dose chemotherapy with stem cell
             transplantation

          -  Adequate renal and hepatic function

        Exclusion Criteria:

          -  Taking selenium supplement before admission
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Molouk Hadjibabaie, Pharma D</last_name>
    <role>Study Chair</role>
    <affiliation>Tehran University of Medical Sciences</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hematology-Oncology &amp; SCT Research Center</name>
      <address>
        <city>Tehran</city>
        <country>Iran, Islamic Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Molouk Hadjibabaie, Pharma D.</last_name>
      <phone>+989122838464</phone>
    </contact>
    <investigator>
      <last_name>Molouk Hadjibabaie, Pharma D</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Zahra Jahangard rafsanjani, Pharma D</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Iran, Islamic Republic of</country>
  </location_countries>
  <link>
    <url>http://horcsct.tums.ac.ir</url>
    <description>Hematology-Oncology &amp; SCT Research Center</description>
  </link>
  <verification_date>May 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 25, 2011</study_first_submitted>
  <study_first_submitted_qc>September 12, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 13, 2011</study_first_posted>
  <last_update_submitted>May 31, 2012</last_update_submitted>
  <last_update_submitted_qc>May 31, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 4, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>BMT</keyword>
  <keyword>HSCT</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mucositis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Selenium</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

